Participate in On Demand Activity
	Activity Details PDF
	Course Materials PDF (online credit only)
	Download Slides
	Complete Post-Test/ Print CE Certificate

	Faculty
	Statement of Need
	Activity Goal
	Learning Objectives
	Target Audience
	Financial Support
	Credit Information

CMEO Webcast

Premiere Date: Monday, August 3, 2009

This activity offers CE credit for:

1. Physicians (ACCME/AMA PRA Category 1)
2. Nurses (CNE)
3. Pharmacists (ACPE)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Tuesday, August 3, 2010

Faculty

Pasi A. Jänne, MD, PhD (Moderator) Associate Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, MA

Giuseppe Giaccone, MD, PhD  Chief of Medical Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD

Statement of Need

Almost 50% of patients diagnosed with NSCLC already have stage 4 disease, and in those with stage 4 disease, only 2% will be alive in one year.(1) After basic diagnostic testing, each patient needs to be tested for genetic alterations such as EGFR, K-RAS, EML4-ALK, and BRAF. Targeting these specific alterations allows NSCLC to be treated as multiple disease entities that can be individually managed with specific agents. Novel agents targeting specific pathways associated with apoptosis, cell proliferation, angiogenesis, and other mechanisms have emerged as a separate and unique therapeutic class delivering promising results in a vast number of malignancies.(2) Clinicians need to know the evidence for targeted therapies—how they may improve outcomes and possibly reduce overall side effect burden. Faculty in this case-based symposium will translate the latest evidence on gene alterations and emerging management strategies to improve individualized treatments and optimize outcomes of patients with NSCLC.

---

1. Lung Cancer in the United States: Facts. National Lung Cancer Partnership; 2008.
2. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther 2007;7:1423-1437.

Activity Goal

To provide an evidence-based review of best practices for diagnosis, treatment, and management NSCLC that can be integrated into clinical practice for improved patient outcomes.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Institute behavioral changes to routinely screen patients for genetic alterations that result in improved diagnosis of non-small cell lung cancer.
• Apply results of genetic testing to the development of targeted treatments for patients with non-small cell lung cancer.
• Compare and contrast new and individualized treatments for non-small cell lung cancer.

The following learning objectives pertain only to those requesting CNE credit:

• Describe behavioral changes to routinely screen patients for genetic alterations that may result in improved diagnosis of NSCLC.
• Identify link between results of genetic testing and the development of targeted treatments for patients with NSCLC.
• Compare and contrast new and individualized treatments for NSCLC.

Target Audience

Physicians, nurse practitioners, nurses, pharmacists, and allied health professionals involved in delivering care to patients diagnosed with lung cancer.

Financial Support

This activity is supported by unrestricted educational grants from Pfizer Inc. and OSI Pharmaceuticals, Inc.

CME Outfitters, LLC, has also provided financial support for this activity.

Co-Sponsorship

This CME activity is co-sponsored by USF Health and CME Outfitters, LLC.

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

USF Health designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

It has been assigned approval code 7ZEK58-10. 1.0 contact hours will be awarded upon successful completion.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 376-999-09-021-H01-P
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations can be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). Otherwise, participants should fully complete and return both the credit request form and activity evaluation located within the course guide for this activity. A certificate or statement of credit will be mailed within 4–6 weeks to all who successfully complete these requirements.

This presentation was selected by the 13th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 13th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.

Disclosure Declaration

It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. USF Health and CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Jänne has disclosed that he receives grants from Pfizer Inc. He serves as a consultant to AVEO Pharmaceuticals, Inc., Boehringer Ingelheim Pharamceuticals, Inc., and Roche. He receives other financial or material support from Genzyme Corporation.

Dr. Giaccone has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, USF Health, the faculty, Pfizer Inc., and OSI Pharmaceuticals, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

MMV-021-080309-90